Pipeline & Programs

Powered by great science

We are utilizing our deep knowledge of drug mechanisms to develop medicines with the potential to provide meaningful differences for people living with psychiatric and neurological conditions.

Pipeline

Our extensive knowledge of how drugs work in the central nervous system fuels our drug discovery and clinical efforts, as we work towards our goal of developing transformative medicines. Our intimate understanding of the biology of muscarinic receptors has propelled our research toward finding novel mechanisms for treating diseases through appropriate activation of the cholinergic system, starting with our lead candidate KarXT.

Product Candidate	Indication	Preclinical Phase 1 Phase 2 Phase 3 Registration
KarXT (xanomeline-trospium) M1-M4 muscarinic agonist	Schizophrenia
	Schizophrenia Adjunctive therapy
	Psychosis in Alzheimer's disease
KAR-2618^* TRPC4/5 inhibitor	Mood & anxiety disorders
KAR-201 Muscarinic-targeted drug candidate	Undisclosed
KAR-301 Muscarinic-targeted drug candidate	Undisclosed
KAR-401 Muscarinic-targeted drug candidate	Undisclosed
KAR-501 Target-agnostic drug candidate^†	Undisclosed

*In-licensed KAR-2618 (formerly GFB-887) from assignment estate of Goldfinch Bio in January 2023; currently in planning stage
†In collaboration with PsychoGenics

KarXT

We are building a portfolio of differentiated therapies led by KarXT, an M1/M4-preferring muscarinic agonist, which has the potential to offer a unique and mechanistically differentiated treatment option for schizophrenia and psychosis in Alzheimer's disease.

Dive Deeper

Clinical trials

Learn more about our clinical trials and review eligibility criteria.

Visit Clinicaltrials.gov

Partnerships & collaborations

We are interested in partnering and collaborating with organizations that share our mission of bringing new treatment options to people living with psychiatric and neurological conditions worldwide.

Learn More

Scientific & medical research

Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial

Lancet 2023

Kaul, I., Sawchak, S., et al.

View

Efficacy of KarXT (Xanomeline-Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

Neuroscience Education Institute (NEI) Congress; 2023 November 9-12.

Kaul, I., Citrome, L., et al.

View

Safety and Tolerability of KarXT (Xanomeline-Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

Neuroscience Education Institute (NEI) Congress; 2023 November 9-12.

Brannan, S., Cutler, A., et al.

View

Structural Basis of Efficacy-Driven Ligand Selectivity at GPCRs

Nature Chem Biol 2023

Powers, A. S., Pham, V., et al.

View

The Clinical Candidate Xanomeline Displays a Binate Orthosteric and Allosteric Binding and Pharmacological Profile at the M4 mACHR

American College of Psychopharmacology (ACNP) Annual Meeting; 2022 December 4-7.

Burger, W., Vuckovic, Z., et al.

View

Muscarinic Acetylcholine Receptors for Psychotic Disorders: Bench-side to Clinic

Trends Pharmacol Sci. 2022 Dec;43(12):1098-1112.

Yohn, S., Weiden, P., et al.

View

Expanded Access Policy

Karuna Therapeutics does not currently accept or grant requests for expanded access to any of its investigational drugs outside of clinical trials. To learn more about our ongoing clinical programs, please visit our ClinicalTrials.gov webpage.